Neurofix is a biotechnology company founded in 2015, focused on the research and development of innovative therapies for the treatment of pathologies related to the Central Nervous System.
Our most advanced product in development is NFX88, a first-in-class drug for the treatment of neuropathic pain associated with spinal cord injury. After successfully completing Phase IIA, the Neurofix team is preparing the last phase of the clinical trial (IIB/III) to verify the efficacy and safety of NFX88 in a larger group of patients from different parts of Europe.
Neuropathic pain is a neurological disorder in which people experience severe chronic pain due to injury or disease of the nervous system. Once neuropathic pain sets in, it is usually permanent and the damage irreversible.
It is estimated to affect 7-8% of the European-American population (Torrance 2006; Bouhassira 2008), although some studies show that it may affect up to 20% of adults. With only 40% of the affected population achieving any relief with current treatments, the management of neuropathic pain remains a complex challenge.
Treatments include antidepressants, cannabinoids, neuromodulators and brain-stimulating drugs, all of which produce significant adverse effects such as dizziness, peripheral oedema, weight gain, ataxia, fatigue, drowsiness and even suicidal behaviour.
The NFX88 drug being developed by Neurofix seeks an alternative method of relieving neuropathic pain in patients with spinal cord injury by targeting the underlying causes of pain rather than relieving its symptoms. This allows neuropathic pain to be addressed specifically.
Learn more about Neurofix, these are the most relevant milestones.
An independent analysis of NFX88’s market access for patients with spinal cord injury and neuropathic pain has been carried out.
On the other hand, the General Shareholders’ Meeting of 19 May 2023 unanimously approved the company’s annual accounts and closed the financing round at a valuation of 22 million euros.
Neurofix has successfully concluded phase IIA of the clinical trial of the drug NFX88, aimed at treating neuropathic pain in patients with spinal cord injury. In this way, it has confirmed the three objectives of the study: 1. The excellent safety profile of NFX88. 2. The intermediate dose tested in the study is sufficient to confirm the efficacy of NFX88. 3. Phase IIA has provided visibility into the preliminary efficacy of NFX88. Efficacy that the company will continue to demonstrate in the next clinical phase.
At the General Shareholders’ Meeting held on June 28, Dr. Antonio Oliviero, clinical neurologist, head of the research group (FENNSI Group) at the Hospital Nacional de Paraplejicos de Toledo, and independent expert, presented his positive conclusions, highlighting that the results of the IIA “clearly confirm the high safety profile” of the drug in patients with paraplegia.
The General Shareholders’ Meeting also unanimously approved the company’s annual accounts and closed the round of financing at a value of 18 million euros.
The AEMPS (Spanish Medicines Agency) confirms to Neurofix the reduction of the sample size (N) of the IIA clinical phase to 44 patients.
Neurofix completes the recruitment of patients from the clinical phase IIA, current Last Patient In (LPI)
Neurofix, after approval at its Extraordinary General Shareholders’ Meeting held on February 15, 2021, approved a round of capital increase through the issuance of 7,246 new shares, with a par value of one euro (€1) and two hundred and six euros (€206) of share premium each, the equivalent value of which consists of monetary contributions, with the aim of continuing with the execution of the clinical trial and further progress on the path towards BME Growth.
At the meeting of the Board of Directors held on April 7, 2021, it was agreed to open said capital increase to third parties through the participatory financing platform Fellow Funders, once the procedure for the exercise of the preferential subscription right of the current shareholders.
Said round was completed with 897,138 euros and will be formalized through the relevant legal procedures in the coming weeks.
Regarding the ongoing clinical trial, in order to achieve a shortening of the deadlines, a reduction in the number of patients necessary to conclude the clinical trial has been requested, from 48 to 44.
Neurofix, after approval at its Extraordinary General Shareholders’ Meeting held on February 15, approved a round of capital increase through the issuance of 7,246 new shares, with a par value of one euro (€1) and two hundred and six euros ( €206) of share premium each, the equivalent of which consists of round monetary contributions to continue with the execution of the clinical trial and continue advancing on the path towards BME Growth. At the meeting of the Board of Directors held on April 7, it was agreed to open said capital increase to third parties through the participatory financing platform Fellow Funders, once the procedure for the exercise of the preferential subscription right of the current shareholders.
Neurofix announces the entry of the Hospital Virgen del Rocío, which will participate in the NFX88 clinical trial to study an experimental treatment for patients suffering from neuropathic pain and spinal cord injury. This new centre is the Hospital Virgen del Rocío in Seville, and its incorporation will speed up the recruitment process and improve the chances of being able to meet the objectives set by the company on schedule despite the circumstances of the health crisis.
Neurofix, at its Extraordinary General Shareholders’ Meeting held on February 15, approved a round of capital increase through the issuance of 7,246 new shares, with a face value of one euro (€1) and two hundred and six euros (€206). of issuance premium each one of them, consisting of its equivalent in round monetary contributions to continue with the execution of the clinical trial and continue advancing on the path towards the BME. Delegation of its execution and subsequent statutory modification to adapt the resulting capital figure in the Board of Directors. In turn, the transfer of the company’s registered office to the Science Park of the University of Salamanca was approved.
Neurofix, at its next Extraordinary General Shareholders’ Meeting to be held on February 15, will submit for approval a round of capital increase through the issuance of 7,246 new shares, with a par value of one euro (€1) and two hundred and six euros (€206) of share premium each one of them, consisting of its equivalent in round monetary contributions to continue with the execution of the clinical trial and continue advancing on the path towards the BME, delegation of its execution and subsequent statutory modification to adapt the resulting capital figure in the Board of Directors. In turn, the transfer of the company’s registered office to the Science Park of the University of Salamanca will be submitted for approval.
Neurofix, at the Extraordinary General Shareholders’ Meeting held on October 26, agreed to the removal of the Sole Administrator and the Modification of the structure of the Company’s administrative body to appoint a Board of Directors, the fixing of the number of directors, the appointment of directors and the appointment of Deloitte as auditor of the company. In addition, a meeting of the Board of Directors was held in which Mr. Mario Grande was appointed as Chief Executive Officer.
This is one more step in the mission of providing the company with the necessary structures for its possible incorporation into BME Growth.
Neurofix announces the entry of two new participating centers in the NFX88 clinical trial, which is to study an experimental treatment in patients suffering from neuropathic pain and who have a spinal cord injury.
These two new centers are the Institut Guttmann in Barcelona and the Hospital de los Madroños in Brunete (Madrid), with their incorporation it will speed up the recruitment process and improve the options for being able to meet the objectives set by the company within the term planned despite the circumstances of the health crisis.
Neurofix has successfully registered the capitalization round approved on June 26, 2020 at the shareholders’ meeting at a valuation of over 10 million euros. In turn, it has received a grant from the Junta de Castilla y León worth 117,214.81 euros.
Neurofix has made a new round of capitalization. On June 26, the shareholders’ meeting approved it at a valuation of over 10 million euros. It will be formalized through the relevant legal procedures in the coming weeks. In addition, Neurofix received support from Iberaval and ICO.
Neurofix has already carried out the transformation of the company from SL into SA, thus advancing in the requirements of the market launch. This transformation was carried out successfully after the corresponding capital increase. Likewise, next month it will carry out a new round of capitalization as a Public Limited Company.
Neurofix Pharma will participate in the major biotechnology events.24 de August de 2023 - 13:33
Neurofix Pharma presents the successful results of its phase IIA clinical trial to institutions and businessmen in Salamanca28 de November de 2022 - 08:46
Mañueco visits the offices of Neurofix Pharma, the first biotech company in Castilla y León to successfully complete phase IIA of a clinical trial11 de November de 2022 - 15:42